August 7, 2019

Less is More: Study Discourages Overuse of Imaging in Paraganglioma Surveillance

Study offers new surveillance guidelines for a rare head and neck tumor

19-ENT-4099-LorenzParaganglionaSurveillance-1-650×450

In the largest study of its kind, Cleveland Clinic surgeons published their research in Head & Neck that demonstrates the incidence of second primary paragangliomas in the head and neck and provides new recommendations on clinical surveillance.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Paragangliomas are rare, slow-growing tumors in the neck, chest, abdomen or pelvis that occur in one in 30,000 to 100,000 people. When a patient has one paraganglioma, they are at greater risk for a second. As less than one-fifth of paragangliomas occur in the head and neck, some guidelines recommend as frequent as annual imaging of the chest, abdomen and pelvis to screen for second tumors after a patient has been treated for a paraganglioma of the head and neck.

Kevin Contrera, MD, MPH, a fourth-year resident in Cleveland Clinic’s Head & Neck Institute and first author on the publication, notes that the study was designed to track longitudinal outcomes of second primary paraganglioma.

“There was minimal data on the management of head and neck paragangliomas after treatment, and imaging surveillance guidelines are inconsistent,” he says.

Study methodologies

The investigators led a retrospective chart review of patients who had a diagnosis of head and neck paraganglioma, including carotid body tumor, glomus vagale, glomus jugulare and glomus tympanicum, between 1990 and 2010. In a cohort of 234 patients, 14 (6.0%) were found to have a second primary paraganglioma in the head and neck, while only three patients (1.3%) ever developed a second primary tumor outside of the head and neck region.

Advertisement

The incidence of a second paraganglioma in the chest, abdomen or pelvis was 2.59 per 1,000 person years, meaning a patient would, on average, require 380 years of repeat imaging to find one additional paraganglioma. However, patients with hereditary paraganglioma were at nearly five-fold greater risk for developing a second primary tumor (HR [hazard ratio] = 4.84, 95% confidence interval [CI]: 1.52-15.43) as compared to patients with negative or no genetic testing. Patients with carotid body tumors, a type of paraganglioma, were also at a greater risk (HR = 3.55, 95% CI: 1.15-10.99).

New recommendations for paraganglioma surveillance

Based on these findings, the authors recommend against the use of routine imaging of the chest, abdomen or pelvis for patients without hereditary paraganglioma. Robert Lorenz, MD, MBA, FACS, head and neck surgeon in Cleveland Clinic’s Head & Neck Institute and corresponding author of the study, notes that this offers an evidence-based perspective that may alter practice for physicians following patients with head and neck paragangliomas. “Genetic testing can play a big role in guiding clinical management as imaging outside the neck may be appropriate every several years for patients with hereditary paragangliomas,” he says.

While there are conflicting guidelines from medical associations on how to follow head and neck paraganglioma patients, data from this study directly opposes opinion-based recommendations of the European Society of Endocrinology, which recommends repeated imaging every one to two years for at least 10 years.

“Repeat imaging is not without risks, and should be balanced with potential benefits,” Dr. Contrera notes. “Overexposure to radiation from CT scans can be potentially harmful, while MRIs can be egregiously expensive for patients and healthcare organizations. Not to mention, there is also a psychological component to repeat testing that can create a lot of anxiety for patients.”

Advertisement

What’s next? A new era in oncologic surveillance

The authors note that the frequency of surveillance imaging of the head and neck is multifaceted, but should take recurrence or progression of the primary tumor into consideration. Future studies are needed to validate these findings in a prospective setting and to better understand the genetic characteristics of head and neck paragangliomas.

“In the era of financial stewardship, we hope this research helps shift oncologic surveillance towards evidence-based care,” says Dr. Lorenz.

Related Articles

Cleveland Clinic physiatrist
March 22, 2024
The Vital Role of Oncology Rehabilitation (Podcast)

New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

Ad